Tobira Therapeutics Inc  

(Public, NASDAQ:TBRA)   Watch this stock  
Find more results for Carol J. Cooper�
6.89
+0.14 (2.07%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.50 - 7.24
52 week 6.24 - 24.31
Open 6.66
Vol / Avg. 22,369.00/44,205.00
Mkt cap 75.63M
P/E     -
Div/yield     -
EPS -1.44
Shares 18.81M
Beta     -
Inst. own 0%
Feb 10, 2016
Tobira Therapeutics Inc at Leerink Partners Global Healthcare Conference - 3:55PM EST - Add to calendar
Nov 10, 2015
Q3 2015 Tobira Therapeutics Inc Earnings Call
Nov 10, 2015
Q3 2015 Tobira Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -153.93% -234.93%
Return on average equity - -
Employees 11 -
CDP Score - -

Address

701 Gateway Blvd Ste 300
SOUTH SAN FRANCISCO, CA 94080-7412
United States - Map
+1-650-7416625 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tobira Therapeutics, Inc., formerly Regado BioSciences, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator that can be used to treat a number of diseases, including non-alcoholic steatohepatitis (NASH), kidney fibrosis, HIV-1 and others. The Company is engaged in clinical studies for CVC, including the CENTAUR Study, an international, randomized Phase IIb study of CVC, and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION, a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease, or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.

Officers and directors

Dennis G. Podlesak Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Laurent Fischer M.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Christopher Peetz Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Helen Jenkins Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Ian Clements Ph.D. Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
Eric Lefebvre M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Carol L. Brosgart M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey H. Cooper CPA Independent Director
Age: 59
Bio & Compensation  - Reuters
Andrew J. Fromkin Independent Director
Age: 48
Bio & Compensation  - Reuters
Patrick J. Heron Independent Director
Age: 44
Bio & Compensation  - Reuters